Denver, Colorado - From telehealth testosterone to transgenic spider silk, today’s tape reflects companies pressing their strategic bets.
Mangoceuticals: TRT Traction Gains Steam
Mangoceuticals (NASDAQ:MGRX) is spotlighting early success for its newly launched $99 per month all-inclusive injectable Testosterone Replacement Therapy (TRT) program under the MangoRx brand. Since its mid-December debut, month-over-month sales have climbed 336%, while customer acquisition costs dropped 54%, a notable combination of top-line acceleration and marketing efficiency.
The company believes TRT will serve as its primary growth driver going forward, alongside oral formulations such as PRIME by MangoRx, powered by Kyzatrex. The global TRT market, according to The Business Research Company’s 2026 edition report, is estimated at roughly $2.1–$2.2 billion in 2025 with projected CAGR of around 3.9%, driven by aging demographics and increasing awareness of hypogonadism.
Founder and CEO Jacob Cohen said the company is encouraged by customer demand and sales acceleration in the injectable TRT product, pointing to streamlined telehealth delivery and targeted cost efficiencies as competitive advantages.
The broader narrative: subscription-style, vertically integrated telehealth continues to test whether pricing transparency and bundled care can unlock durable recurring revenue in men’s health.
Kraig Biocraft Laboratories: Spider Silk Nears Industrial Scale
Kraig Biocraft Laboratories (OTCQB:KBLB) is entering what could be a defining commercial phase in transgenic animal biotechnology. The company is preparing to deploy approximately one million proprietary spider silk silkworm eggs across three production facilities in Vietnam, targeting up to 10 metric tons per month of recombinant spider silk cocoons beginning in March.
The company’s platform, validated in peer-reviewed research published in the Proceedings of the National Academy of Sciences, demonstrated that transgenic silkworms could produce composite silk fibers with toughness comparable to native spider dragline silk. Now, the focus shifts from validation to scale.
Management has disclosed engagement with three nationally recognized global brands, including a luxury fashion house, a performance sportswear company, and an athletic equipment manufacturer, with initial shipments expected upon completion of material preparation.
The historical backdrop is instructive. The only sustained commercial precedent for transgenic animal biotech remains ATryn, developed by Genzyme and later folded into Sanofi (NASDAQ:SNY) following its $20.1 billion acquisition of Genzyme in 2011. If Kraig achieves sustained commercial output from a naturally spun, biodegradable structural fiber, it would mark a rare milestone in biological manufacturing.
Opendoor Technologies: Opendoor 2.0 Shows Operational Shifts
Opendoor (NASDAQ:OPEN) reported Q4 and full-year 2025 results highlighting operational recalibration under its “Opendoor 2.0” strategy.
Key operating metrics:
Homes purchased up 46% quarter-over-quarter
Inventory days in possession reduced 23%
Fixed operating expenses down both sequentially and year-over-year
October 2025 acquisition cohort tracking as strongest October cohort in company history by contribution margin
Revenue for Q4 came in at $736 million versus $1.084 billion a year earlier, while full-year revenue declined to $4.37 billion from $5.15 billion. Net loss widened in Q4, but adjusted EBITDA improved year-over-year.
CEO Kaz Nejatian said the quarter demonstrates execution against a four-step transformation plan aimed at breakeven adjusted net income by the end of 2026 on a 12-month forward basis.
The market question remains whether improved cohort economics and faster resale velocity can outpace macro housing headwinds and restore durable profitability.
Envirotech Vehicles& Azio AI: ASIC Validation Phase Begins
Azio AI announced receipt of its first purchase order from Envirotech Vehicles (NASDAQ:EVTV) for 28 next-generation ASIC compute systems, with payment received in full.
The ASIC systems are slated for deployment within EVTV’s liquid-immersion-cooled modular container infrastructure. During the validation phase, the systems are expected to run SHA-256 compute workloads generating Bitcoin (BTC) yields, while benchmarking high-density power utilization, immersion cooling efficiency, and uptime resilience.
No assurances were provided regarding operational performance or digital asset yields, but the announcement underscores the ongoing convergence of AI infrastructure engineering and energy-integrated compute deployment.
Guardforce AI: $5M Share Repurchase Authorization
Guardforce AI’s (NASDAQ:GFAI) board approved a share repurchase program authorizing up to $5 million in buybacks over the next year.
Chairwoman and CEO Lei Wang said the authorization reflects confidence in the company’s fundamentals, citing its secured logistics base and AI Agent platform roadmap. The program allows opportunistic repurchases through open-market or negotiated transactions, though it does not obligate specific share purchases.
In a market increasingly rewarding disciplined capital allocation, small-cap buybacks often function as both valuation statements and liquidity signals.
CDT Equity: Strategic Stake in Sarborg
CDT Equity (NASDAQ:CDT) entered into a transaction to acquire a 20% stake in Sarborg Limited, an agentic AI signature intelligence company. Total consideration totals $115 million, primarily via issuance of common stock and pre-funded warrants, with an additional $8 million deferred consideration tied to future fundraising.
The move formalizes an existing collaboration leveraging Sarborg’s signature-based analytical platform across biological, chemical, and industrial datasets. CEO Dr. Andrew Regan said the transaction strengthens strategic alignment and creates additional avenues for long-term value creation.
The broader theme: AI-driven analytical platforms continue to embed themselves across asset evaluation pipelines, particularly in life sciences and materials innovation.
For more information about Kraig Labs’ spider silk technology and partnership opportunities, visit www.kraiglabs.com
Please click here to read the full Kraig Labs analyst report on 247marketnews.com.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) is a biotechnology company focused on the development and commercialization of spider silk-based fiber technologies. Through its proprietary silkworm-based genetic engineering platform, Kraig Labs produces high-performance, cost-effective, and scalable spider silk materials for use in defense, performance apparel, technical textiles, and medical applications.
About 24/7 Market News
In today's fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you're an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247marketnews.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.
PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 24/7 is a third-party media provider that owns KBLB shares, which are on deposit and may be sold at the editor’s discretion, and has been compensated for providing ongoing KBLB market outreach and other services.. This press release may include technical analysis and should not be construed as financial or investment advice. Trading stocks involves risks, and readers should consult with their financial advisor before making investment decisions.
For further information, please visit 247marketnews.com or https://go.247marketnews.com/kblb-disclosure/
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.
